Switzerlandmolecularpartners.com
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich-Schlieren, Switzerland, with a presence in Concord, Massachusetts, United States. It develops DARPin therapeutics, a class of engineered protein drugs designed for targeted applications, primarily in oncology and radiotherapeutics.
The company maintains an active pipeline including radio-DARPin candidates such as MP0712, co-developed with Orano Med for small cell lung cancer and neuroendocrine tumors using lead-212 alpha therapy. Additional programs encompass MP0317 and MP0533 in clinical evaluation. Molecular Partners is publicly listed on the SIX Swiss Exchange and NASDAQ under the ticker MOLN and has entered development agreements, including with Eckert & Ziegler for radiopharmaceutical manufacturing.
None yet. When a new project in the record names Molecular Partners as owner, partner or investor, it shows here.
Funds will build the Advanced Thorium Extraction Facility to scale thorium‑228 supply for lead‑212 targeted alpha therapies and feed ATLabs.
